174 related articles for article (PubMed ID: 38702144)
1. CHMP2A regulates broad immune cell-mediated antitumor activity in an immunocompetent in vivo head and neck squamous cell carcinoma model.
Yun J; Saddawi-Konefka R; Goldenson B; Al-Msari R; Bernareggi D; Thangaraj JL; Tang S; Patel SH; Luna SM; Gutkind JS; Kaufman D
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702144
[TBL] [Abstract][Full Text] [Related]
2. CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity.
Bernareggi D; Xie Q; Prager BC; Yun J; Cruz LS; Pham TV; Kim W; Lee X; Coffey M; Zalfa C; Azmoon P; Zhu H; Tamayo P; Rich JN; Kaufman DS
Nat Commun; 2022 Apr; 13(1):1899. PubMed ID: 35393416
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
[TBL] [Abstract][Full Text] [Related]
4. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
[TBL] [Abstract][Full Text] [Related]
5. An HNSCC syngeneic mouse model for tumor immunology research and preclinical evaluation.
Fu Y; Tian G; Li J; Zhang Z; Xu K
Int J Mol Med; 2020 Oct; 46(4):1501-1513. PubMed ID: 32700748
[TBL] [Abstract][Full Text] [Related]
6.
Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
[TBL] [Abstract][Full Text] [Related]
7. Landscape of natural killer cell activity in head and neck squamous cell carcinoma.
Charap AJ; Enokida T; Brody R; Sfakianos J; Miles B; Bhardwaj N; Horowitz A
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428584
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
Greene S; Robbins Y; Mydlarz WK; Huynh AP; Schmitt NC; Friedman J; Horn LA; Palena C; Schlom J; Maeda DY; Zebala JA; Clavijo PE; Allen C
Clin Cancer Res; 2020 Mar; 26(6):1420-1431. PubMed ID: 31848188
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of HLA-B-associated transcript 3 impairs the tumoricidal effect of natural killer cells through promoting the T cell immunoglobulin and mucin domain-containing-3 signaling in a mouse head and neck squamous cell carcinoma model.
Yang J; Xiang J; Zhu M; Zhao Y; Zhou L; Hu B; Wang C
Immunobiology; 2022 Jan; 227(1):152127. PubMed ID: 34968777
[TBL] [Abstract][Full Text] [Related]
10. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
[TBL] [Abstract][Full Text] [Related]
11. An Immunocompetent Mouse Model of HPV16(+) Head and Neck Squamous Cell Carcinoma.
Carper MB; Troutman S; Wagner BL; Byrd KM; Selitsky SR; Parag-Sharma K; Henry EC; Li W; Parker JS; Montgomery SA; Cleveland JL; Williams SE; Kissil JL; Hayes DN; Amelio AL
Cell Rep; 2019 Nov; 29(6):1660-1674.e7. PubMed ID: 31693903
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
13. CDX2 enhances natural killer cell-mediated immunotherapy against head and neck squamous cell carcinoma through up-regulating CXCL14.
Wang H; Nan S; Wang Y; Xu C
J Cell Mol Med; 2021 May; 25(10):4596-4607. PubMed ID: 33733587
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies.
Friedman J; Morisada M; Sun L; Moore EC; Padget M; Hodge JW; Schlom J; Gameiro SR; Allen CT
J Immunother Cancer; 2018 Jun; 6(1):59. PubMed ID: 29925431
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of natural killer cell therapy combined with chemoradiotherapy in murine models of head and neck squamous cell carcinoma.
Jung EK; Chu TH; Kim SA; Vo MC; Nguyen VT; Lee KH; Jung SH; Yoon M; Cho D; Lee JJ; Yoon TM
Cytotherapy; 2024 Mar; 26(3):242-251. PubMed ID: 38142382
[TBL] [Abstract][Full Text] [Related]
19. An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck.
Pinette A; McMichael E; Courtney NB; Duggan M; Benner BN; Choueiry F; Yu L; Abood D; Mace TA; Carson WE
Cancer Immunol Immunother; 2019 Aug; 68(8):1379-1389. PubMed ID: 31338557
[TBL] [Abstract][Full Text] [Related]
20. Landscape of innate lymphoid cells in human head and neck cancer reveals divergent NK cell states in the tumor microenvironment.
Moreno-Nieves UY; Tay JK; Saumyaa S; Horowitz NB; Shin JH; Mohammad IA; Luca B; Mundy DC; Gulati GS; Bedi N; Chang S; Chen C; Kaplan MJ; Rosenthal EL; Holsinger FC; Divi V; Baik FM; Sirjani DB; Gentles AJ; Newman AM; Freud AG; Sunwoo JB
Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34244432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
